✦ LIBER ✦

Pharmacokinetics of quinine in young and elderly subjects

✍ Scribed by Sompon Wanwimolruk; Stephen Chalcroft; Peter F. Coville; A.John Campbell

Publisher: Elsevier Science
Year: 1991
Tongue: English
Weight: 431 KB
Volume: 85
Category: Article
ISSN: 0035-9203
DOI: 10.1016/0035-9203(91)90423-v

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparative single dose and steady-state

Comparative single dose and steady-state pharmacokinetics of bevantolol in young and elderly subjects

✍ A. Selen; A. W. Kinkel; A. C. Darke; D. S. Greene; P. G. Welling 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 721 KB

Pharmacodynamics and pharmacokinetics of

Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects

✍ A. Auteri; A. Mosca; N. Lattuada; M. Luzzana; L. Zecca; D. Radice; B. P. Imbimbo 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 382 KB

Bioavailability and pharmacokinetics of

Bioavailability and pharmacokinetics of ketanserin in elderly subjects

✍ M. Kurowski 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 756 KB

Pharmacokinetics of enprofylline in heal

Pharmacokinetics of enprofylline in healthy elderly subjects

✍ E. Lunell; O. Borgå 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 391 KB

Memory complaints in young and elderly s

Memory complaints in young and elderly subjects

✍ Christian Derouesné; Lucette Lacomblez; Stéphanie Thibault; Monique Leponcin 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

Objective. To compare the quantitative and qualitative aspects of memory complaints in cognitively normal subjects aged under and above 50 years. Setting. A memory clinic located in a general hospital in a suburb of Paris oering direct access to subjects. Design. Retrospective review of the ®les o

Single-dose pharmacokinetics of nefazodo

Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment

✍ R. H. Barbhaiya; D. S. Greene; U. A. Shukla 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 658 KB

The single-dose pharmacokinetics of nefazodone (NEF) and its metabolites hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were examined in 12 healthy younger subjects < 55 years of age (YNG), 12 elderly subjects > 65 years of age (ELD), 12 patients with biopsy proven hepatic cirrhosis